A large Canadian study of patients with inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, reports that a high overall rate of adherence to subcutaneous anti-TNFs.
Anti—tumor necrosis factor (TNF) therapies are the most widely used biologics in rheumatology in Canada, due to many years of clinical experience and provincial reimbursement criteria. A large Canadian study of patients with inflammatory diseases, including rheumatoid arthritis (RA), psoriatic arthritis (PA), and ankylosing spondylitis (AS), reports that a high overall rate of adherence to subcutaneous anti-TNFs (76% of patients).
In addition, the data show that patients taking golimumab (Simponi) had the highest adherence compared with other subcutaneous anti-TNFs: adalimumab (Humira), etanercept (Enbrel), and certolizumab pegol (Cimzia). The study also confirmed previous research showing that patients have better adherence to medications with longer versus shorter dosing intervals, and supported the inverse relationship between dosing frequency and adherence reported in various studies with different medication classes.
The study, published in the July 2017 issue of BMJ Open, was supported by Janssen, Canada, the manufacturer of golimumab. The finding is important because nonadherence to therapy is an important, modifiable factor that may compromise patient outcomes, said lead author Peter Bhoi, of Janssen Inc. Dosing intervals for subcutaneous anti-TNFs were evaluated in order to assess the proportion of patients whose treatment needed to be intensified (by shortening the dosing interval) during the course of a 2-year follow up. “We found that shortening of the dosing interval was observed in all the [subcutaneous anti-TNF] cohorts, and that the proportions of patients were comparable between the 4 drugs,” the study’s authors said. “To the best of our knowledge, this it he first detailed report on shortening of the dosing interval across different [subcutaneous anti-TNFs].”
The researchers used prescribing data from January 1, 2010, to June 30, 2012, and followed patients for 24 months through June 30, 2014. Patients included in the study were adults newly prescribed a subcutaneous anti-TNF with at least 3 prescriptions, and retained on therapy for at least 24 months. The study included 4035 patients, with 683 (16.9%) receiving golimumab; 1400 (34.7%) receiving adalimumab; 1764 (43.7%) receiving etanercept; and 187 (4.6%) receiving certolizumab pegol. The study included over half of the overall Canadian population of patients with inflammatory rheumatic diseases.
The researchers report that the proportion of adherent patients in the golimumab cohort (n = 595, 87%; P < .0001) was greater than that of adalimumab- (n = 1044, 75%), etanercept- (n = 1285, 73%), and certolizumab pegol-treated patients (n = 132, 71%).
In addition, the number of patients receiving a biologic at a shorter dosing interval was similar among cohorts:
In conclusion, this real-life study evaluating adherence to anti-TNFs in inflammatory diseases, using data from the Canadian administrative databases, demonstrates considerably high adherence rates. The finding that golimumab has better adherence compared with the other subcutaneous anti-TNFs could be explained, in part, by its simpler, less frequent dosing regimen. Further studies are needed to investigate the reasons for the difference in adherence between golimumab and other subcutaneous anti-TNFs, and to evaluate the impact of this improved adherence on clinical and health-economic outcomes.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.